GSK Past Earnings Performance
Past criteria checks 2/6
GSK has been growing earnings at an average annual rate of 22.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 3.7% per year. GSK's return on equity is 26.5%, and it has net margins of 14%.
Key information
22.7%
Earnings growth rate
22.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | 3.7% |
| Return on equity | 26.5% |
| Net Margin | 14.0% |
| Next Earnings Update | 27 Jul 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GSK makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 36,476 | 5,114 | 10,563 | 4,951 |
| 31 Dec 21 | 34,114 | 4,385 | 10,190 | 4,877 |
| 30 Sep 21 | 33,326 | 4,313 | 10,028 | 4,811 |
| 30 Jun 21 | 32,895 | 4,389 | 10,000 | 4,681 |
| 31 Mar 21 | 32,427 | 5,257 | 10,029 | 4,678 |
| 31 Dec 20 | 34,099 | 5,749 | 10,503 | 4,678 |
| 30 Sep 20 | 34,259 | 6,371 | 10,719 | 4,537 |
| 30 Jun 20 | 34,998 | 6,679 | 11,085 | 4,648 |
| 31 Mar 20 | 35,183 | 5,380 | 10,993 | 4,519 |
| 31 Dec 19 | 33,754 | 4,645 | 10,962 | 4,405 |
| 30 Sep 19 | 33,052 | 4,561 | 10,103 | 4,266 |
| 30 Jun 19 | 31,759 | 4,427 | 9,575 | 4,065 |
| 31 Mar 19 | 31,260 | 3,904 | 9,488 | 3,887 |
| 31 Dec 18 | 30,821 | 3,623 | 9,500 | 3,799 |
| 30 Sep 18 | 30,263 | 1,862 | 9,234 | 3,755 |
| 30 Jun 18 | 30,014 | 1,656 | 9,185 | 3,696 |
| 31 Mar 18 | 30,024 | 1,035 | 9,143 | 3,890 |
| 31 Dec 17 | 30,186 | 1,532 | 9,424 | 3,925 |
| 30 Sep 17 | 30,133 | 2,335 | 9,303 | 3,886 |
| 30 Jun 17 | 29,832 | 1,931 | 9,260 | 3,863 |
| 31 Mar 17 | 29,044 | 1,676 | 9,017 | 3,604 |
| 31 Dec 16 | 27,889 | 912 | 8,852 | 3,550 |
| 30 Sep 16 | 26,589 | 301 | 8,553 | 3,370 |
| 30 Jun 16 | 25,174 | 31 | 8,025 | 3,226 |
| 31 Mar 16 | 24,530 | 615 | 8,097 | 3,163 |
| 31 Dec 15 | 23,923 | 8,422 | 9,232 | 3,560 |
| 30 Sep 15 | 23,823 | 9,809 | 7,810 | 3,218 |
Quality Earnings: 001102657 has high quality earnings.
Growing Profit Margin: 001102657's current net profit margins (14%) are lower than last year (16.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 001102657's earnings have grown significantly by 22.7% per year over the past 5 years.
Accelerating Growth: 001102657's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 001102657 had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-30.2%).
Return on Equity
High ROE: Whilst 001102657's Return on Equity (26.52%) is high, this metric is skewed due to their high level of debt.